期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Finding the Needle in the Haystack—An Unusual Case of Astasia-Abasia Following Sacro-Iliac Joint Injection for Chronic Low Back Pain
1
作者 Gurmukh Das Punshi Andrew Purcell Camillus Power 《Pain Studies and Treatment》 2021年第1期1-6,共6页
We present the case of a 60 yrs old male who, following a routine, uneventful, fluoroscopically guided L5/S1 facet joint rhizolysis and sacro-iliac joint (SIJ) injection developed an unexpected inability to stand or w... We present the case of a 60 yrs old male who, following a routine, uneventful, fluoroscopically guided L5/S1 facet joint rhizolysis and sacro-iliac joint (SIJ) injection developed an unexpected inability to stand or walk, a condition known as astasia-abasia. Initial concern had been that this neurological phenomenon was as a result of complications of his chronic pain intervention. Despite an essentially normal neurological examination and dedicated battery of neurological imaging and special testing, no cause was identified. Over a 7-day period of in-patient admission and physical rehabilitation symptoms resolved entirely. In the course of the workup for this episode, it was suggested that the phenomenon was the result of a side effect of dexamfetamine, an agent that had been prescribed for the patient by his neurologist for treatment of his narcolepsy. On the back of this episode, this treatment was discontinued by his neurologist following an outpatient consultation. Subsequent repeated SIJ injections were entirely uneventful and the patient experienced no further occurrences of this phenomenon. 展开更多
关键词 Chronic Low Back Pain Sacroiliac Joint Injection dexamfetamine Astasia-Abasia
下载PDF
氯吡格雷联合依达拉奉右莰醇注射用浓溶液治疗对进展性脑卒中血清Hcy、FIB及CRP水平的影响
2
作者 牛峰志 李家辉 +2 位作者 姚昕彤 龚燕丽 常群 《分子诊断与治疗杂志》 2024年第9期1755-1758,共4页
目的探究氯吡格雷联合依达拉奉右莰醇注射用浓溶液治疗对进展性脑卒中血清同型半胱氨酸(Hcy)、纤维蛋白原(FIB)及C反应蛋白(CRP)水平的影响。方法选取2021年1月至2024年1月临泉县人民医院收治的122例进展性脑卒中患者,根据治疗方法的差... 目的探究氯吡格雷联合依达拉奉右莰醇注射用浓溶液治疗对进展性脑卒中血清同型半胱氨酸(Hcy)、纤维蛋白原(FIB)及C反应蛋白(CRP)水平的影响。方法选取2021年1月至2024年1月临泉县人民医院收治的122例进展性脑卒中患者,根据治疗方法的差异将其分为对照组(予以氯吡格雷治疗,n=60例)与试验组(予以氯吡格雷联合依达拉奉右莰醇注射用浓溶液治疗,n=62例)。对比两组临床疗效、Hcy、CRP水平、凝血功能[纤维蛋白原浓度(FIB)、活化部分凝血活酶时间(APTT)及凝血酶原时间(PT)]及不良反应发生情况。结果试验组临床总有效率(95.16%)比对照组临床总有效率(75.00%)高,差异有统计学意义(P<0.05)。治疗7 d后,两组Hcy、CRP水平均降低,且试验组Hcy、CRP水平比对照组低,差异有统计学意义(P<0.05)。治疗7 d后,两组FIB水平下降,APTT、PT水平上升,且试验组FIB水平比对照组低,APTT、PT水平比对照组,差异有统计学意义(P<0.05)。对照组、试验组不良反应总发生率分别为10.00%、11.29%,两组比较差异无统计学意义(P>0.05)。结论氯吡格雷联合依达拉奉右莰醇注射用浓溶液治疗可有效提高进展性脑卒中患者临床疗效,改善血清Hcy、FIB、CRP水平,具有较高安全性。 展开更多
关键词 氯吡格雷 依达拉奉右莰醇注射用浓溶液 进展性脑卒中 Hcy FIB CRP
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部